LGD-4033 powder, also known as VK5211 and Ligandrol, is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis, currently under development by Ligand Pharmaceuticals. LGD-4033 was safe, had favorable pharmacokinetic profile, reated to cure muscle wasting linked with acute and chronic diseases, age-related muscle loss and cancer.
02 LGD-4033 powder (1165910-22-4) video
03 LGD-4033 powder Base Information
|Chemical name||LGD-4033; LGD 4033; LGD4033; VK5211; VK-5211; VK 5211; Ligandrol.|
|Molecular Weight||338.253 g/mol|
|Melting Point||105 – 106 °C|
|Half Life||24-36 hours|
|Solubility||Soluble in DMSO, not in water|
|Storage Condition||Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years).|
|Application||LGD-4033 (VK5211, Ligandrol) is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting and osteoporosis,|
04 LGD-4033 powder General Description
LGD 4033 powder is a fairly new oral selective androgen receptor modulator (SARM). SARMs have received a lot of attention recently, both in the medical community and among people who are seeking physical performance and appearance enhancement. Scientists are exploring the ways SARMs could be used to overcome muscle wasting and bone diseases.
05 LGD-4033 powder (1165910-22-4) History
LGD-4033 was developed by the pharmaceutical Ligand (hence the name), with the goal in mind to promote healing properties in the body. This was to come in the form of limiting ‘wasting conditions’. As well as stimulating positive activity in bones and muscles.
The exclusivity of having an effect on certain areas is the primary reason it is sought out in lieu of anabolic steroids. Steroids help in building muscle.
06 LGD-4033 (1165910-22-4) Mechanism Of Action
SARMs are selective to muscles and bones as they:
Navigate to muscles and bones to a greater extent
Muscles and bones may have more sensors for them (so-called coregulators)
Activate androgen receptors but are chemically different from steroids
Being nonsteroidal, SARMs are not substrates for 5 alpha-reductase or CYP19 aromatase, which prevents their conversion to the testosterone metabolite DHT or estrogen
However, not all SARMs are equally muscle-selective. Some SARMs were abandoned due to their potential for serious side effects. On the other hand, a handful of SARMs are being developed as potential birth control pills for men since they act on the pituitary.
The first generation SARMs (developed by Ligand Pharmaceuticals and including LGD 4033) had a modest but undeniable effect on lean body mass gains. The second generation of SARMs we are yet to see may be even more potent and selective.
07 LGD-4033 (1165910-22-4) Application
LGD-4033 or Ligandrol or Anabolicum is a research chemical developed by Ligand Pharmaceuticals for its potential therapeutic applications in preventing muscle wasting caused due to cancer, increasing diminished bone density due to osteoporosis and certain medications, and in preventing muscle loss due to aging. In clinical trials, LGD 4033 increased lean body mass and strength, decreased body fat, improved wellbeing, and enhanced the healing process. However, the doses and goals of clinical studies differ from its real-world use.
It is a selective androgenic receptor modulator or SARM that binds to androgen receptors in the muscle and bone tissue. Androgen receptors in the prostate, the reproductive system and the endocrine system are left untouched.
Eventually, Viking took over the research. And in some places, the compound may be available under a new name, VK5211.
Along with Ostarine or MK-2866, it happens to be the most popular SARM in the bodybuilding circuit.
08 LGD-4033 (1165910-22-4) More research
LGD 4033 raises anabolic activity in the muscles and bones while reducing muscle wasting and bone breakdown. Recent clinical trials attest to the best and safest way to use it to an extent.
LGD 4033 was initially created by Ligand Pharmaceuticals, hence the name “Ligandrol”. Viking Therapeutics took over LGD 4033 research in the meantime, renaming it to VK5211. This small pharma company is researching LGD 4033/VK5211 for hip fracture recovery. They state that it will hopefully produce all the benefits of testosterone with improved safety, aiming to get approval for its clinical use sometime in the future.
09 LGD-4033 (1165910-22-4) Document Download
10 LGD-4033 (1165910-22-4) Reference
1: Thevis M, Lagojda A, Kuehne D, Thomas A, Dib J, Hansson A, Hedeland M, Bondesson U, Wigger T, Karst U, Schänzer W. Characterization of a non-approved selective androgen receptor modulator drug candidate sold via the Internet and identification of in vitro generated phase-I metabolites for human sports drug testing. Rapid Commun Mass Spectrom. 2015 Jun 15;29(11):991-9. doi: 10.1002/rcm.7189. PubMed PMID: 26044265.
2: Krug O, Thomas A, Walpurgis K, Piper T, Sigmund G, Schänzer W, Laussmann T, Thevis M. Identification of black market products and potential doping agents in Germany 2010-2013. Eur J Clin Pharmacol. 2014 Nov;70(11):1303-11. doi: 10.1007/s00228-014-1743-5. Epub 2014 Aug 30. PubMed PMID: 25168622.
3: Dalton JT, Taylor RP, Mohler ML, Steiner MS. Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer. Curr Opin Support Palliat Care. 2013 Dec;7(4):345-51. doi: 10.1097/SPC.0000000000000015. Review. PubMed PMID: 24189892.
- 01. Overview
- 02. LGD-4033 powder (1165910-22-4) video
- 03. LGD-4033 powder Base Information
- 04. LGD-4033 powder General Description
- 05. LGD-4033 powder (1165910-22-4) History
- 06. LGD-4033 (1165910-22-4) Mechanism Of Action
- 07. LGD-4033 (1165910-22-4) Application
- 08. LGD-4033 (1165910-22-4) More research
- 09. LGD-4033 (1165910-22-4) Document Download
- 10. LGD-4033 (1165910-22-4) Reference